Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taranabant in Obese Patients (NCT00131404)
NCT00131404Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of taranabant in obesity (5 arms), sponsored by Merck & Co. Primary endpoints: Change in body weight at 156 weeks and Safety and tolerability at 156 weeks. Started Sep 2005; status: terminated.
02
Drugs
taranabant
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00131404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131404.